BrightSpring Health Services, Inc. Common Stock · BTSG · FY2026 Q3 · Calendar Q4 2026
BrightSpring posts broad Q3 growth while IRA pressure persists
The quarter supports a constructive operating thesis: broad demand, LDD expansion, home-health growth, and operating improvements are driving momentum. The thesis remains conditional on managing IRA pressure, sustaining specialty growth, and executing integrations and new services.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about BTSG FY2026 Q3
Transcript, numbers and history already loadedFree account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior quarter, management described continued acceleration in the reported operating picture: the Amedisys/LHC branches contributed $76 million of revenue and $35 million of adjusted EBITDA in Q3, while the company added 19 LDDs year to date. Management also highlighted a $50 million quarterly IRA impact on home and community pharmacy and rapid deployment of AI and automation tools.
Guidance delta
Management maintained its 2026 outlook and described a 2027 organic adjusted EBITDA growth target of 15% to 20%.
Key takeaways
- Management described strong Q3 growth across Pharmacy Solutions and Provider Services, with continued momentum in specialty, infusion, home health, hospice, rehab, and personal care.
- Pharmacy Solutions benefited from 19 LDD launches year to date and 34% specialty and infusion revenue growth.
- Provider Services benefited from 58% year-over-year home-health census growth and continued expansion.
- Management highlighted lower leverage, $204 million of operating cash flow in the quarter, and an operating cash flow outlook above $700 million.
- The main offset remains IRA-related pressure on home and community pharmacy, alongside integration and execution demands.
Management priorities
- Continue expanding the LDD portfolio and specialty and infusion offerings.
- Expand chronic-therapy infusion suites, clinic upgrades, and therapeutic categories.
- Roll out IG Connect and virtual primary-care capabilities.
- Pursue strategic acquisitions in home health, hospice, rehab, and specialty pharmacy.
- Increase use of AI and automation across clinical, operational, documentation, and staffing functions.
Follow BTSG with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeCompany context
Snapshot as of publicationBrightSpring Health Services, Inc. operates across the United States, offering a range of healthcare solutions directly within patients' homes and local communities. The company's extensive platform focuses on providing crucial pharmacy and medical provider services, including both clinical care and supportive assistance, to individuals covered by Medicare, Medicaid, and private insurance. Patients receive care from a dedicated team of clinical professionals and licensed pharmacists. Formerly known as Phoenix Parent Holdings Inc., the company officially adopted the name BrightSpring Health Services, Inc. in May 2021. Founded in 1974, its headquarters are located in Louisville, Kentucky.
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +1.2% | AbbVie Q3 2026: Guidance Raised as Immunology Drives Growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | — | +9.9% | BrightSpring Q3: Pharmacy Growth Offsets IRA Pressure |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +12.3% | Regeneron: Core Brands Grow as Pipeline Milestones Advance |
| ILMN Illumina, Inc. | FY2026 Q3 · Calendar Q4 2026 | +19.1% | -16.8% | Illumina raises FY2026 outlook as clinical sequencing demand holds up |
| DVA DaVita Inc. | FY2026 Q3 · Calendar Q4 2026 | +7.0% | -6.8% | DaVita’s expanded HD rollout and IKC progress support a narrowed outlook |
| SYK Stryker Corporation | FY2026 Q3 · Calendar Q4 2026 | -0.8% | -5.0% | Stryker cuts guidance as hip and knee demand slows |
Latest beats and misses
Who reports nextBeat on EPS
- WYFY2026 Q3 · October 29, 2026+128.3% EPS+3.0% move
- LNTFY2026 Q3 · October 29, 2026+16.0% EPS+1.4% move
- MTZFY2026 Q3 · October 29, 2026+0.3% EPS+0.8% move
- ERIEFY2026 Q3 · October 29, 2026+2.1% EPS+5.3% move
- IRFY2026 Q3 · October 29, 2026+18.5% EPS+0.2% move
- VLTOFY2026 Q3 · October 29, 2026+8.3% EPS+9.8% move
Missed on EPS
- VALEFY2026 Q3 · October 29, 2026-24.6% EPS+1.9% move
- AMZNFY2026 Q3 · October 29, 2026-4.1% EPS-1.6% move
- SYKFY2026 Q3 · October 29, 2026-0.8% EPS-5.0% move
- DLR-PJFY2026 Q3 · October 29, 2026-8.4% EPS— move
- DLRFY2026 Q3 · October 29, 2026-8.4% EPS-3.0% move
- EGFY2026 Q3 · October 28, 2026-18.8% EPS+3.5% move
Get the BTSG recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T15:10:33.701335+00:00
- FN2 earnings calendar · 2026-10-30T01:23:13.979536+00:00
- Polygon adjusted daily market bars · 2026-10-30T20:00:43.797367+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-30T20:00:43.794579+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-30. For educational purposes only; not investment advice.